Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  American Journal of Pathology

• Publication date

  2016-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ajpath.2015.12.029PMID 26993207
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Japanese

  2018cited by this paper
• Cancer statistics, 2015

  2015cited by this paper
• Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.

  2014cited by this paper
• Epimorphin-Induced MET Sensitizes Ovarian Cancer Cells to Platinum

  2013cited by this paper
• Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer.

  2013cited by this paper
• PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction

  2013cited by this paper
• Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells

  2013cited by this paper
• A Collagen-Remodeling Gene Signature Regulated by TGF-β Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer

  2013cited by this paper
• Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer

  2012cited by this paper
• EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer

  2012cited by this paper
• Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.

  2012cited by this paper
• Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.

  2012cited by this paper
• Reclassification of serous ovarian carcinoma by a 2‐tier system

  2012cited by this paper
• High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway

  2012cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• The genesis and evolution of high-grade serous ovarian cancer

  2010cited by this paper
• Regulation of Excision Repair Cross-Complementation Group 1 by Snail Contributes to Cisplatin Resistance in Head and Neck Cancer

  2010cited by this paper
• Gene Expression Profile for Predicting Survival in Advanced-Stage Serous Ovarian Cancer Across Two Independent Datasets

  2010cited by this paper
• Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

  2009cited by this paper
• Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.

  2009cited by this paper
• Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.

  2009cited by this paper
• Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

  2009cited by this paper
• Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems

  2009cited by this paper
• Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

  2008cited by this paper
• Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

  2007cited by this paper
• The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel

  2007cited by this paper
• From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

  2005cited by this paper
• Grading Ovarian Serous Carcinoma Using a Two-Tier System

  2004cited by this paper
• The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin

  2004cited by this paper
• Diverse tumorigenic pathways in ovarian serous carcinoma.

  2002cited by this paper
• Histopathologic grading of ovarian carcinoma: a review and proposal.

  2000cited by this paper
• Cancer statistics

  1989cited by this paper
• The American journal of pathology

  year unknowncited by this paper

• Oligoclonal B cell expansion and passenger fusion genes predict response to Nivolumab in recurrent ovarian cancer: phase II Kyoto trial

  2026cites this paper
• HE4 Might Participate in Extracellular Matrix Remodeling in Ovarian Cancer via Activation of Fibroblasts

  2025cites this paper
• STAT1β modulates the tumor immune microenvironment to improve prognosis in ovarian cancer: a comprehensive study of transcriptional and protein expression differences

  2025influential citation
• Transforming treatment paradigms: Focus on personalized medicine for high‐grade serous ovarian cancer

  2025cites this paper
• Carcinomas exhibiting epithelial–mesenchymal transition manifest an M2 macrophage-enriched tumor immune microenvironment

  2025cites this paper
• Combinatorial organoid mutagenesis screen reveals gene constellations driving malignant transformation, pathology and chemosensitivity in high-grade serous ovarian carcinoma

  2025cites this paper
• Unlocking prognostic potential: A genomic signature of caloric restriction in patients with epithelial ovarian cancer

  2025cites this paper
• Intra-Tumoral Lymphocytic Infiltration Is Associated with Favorable Prognosis in Suboptimal Surgery in High-Grade Serous Ovarian Carcinoma

  2025cites this paper
• Evaluation of the prognostic potential of histopathological subtyping in high-grade serous ovarian carcinoma

  2024influential citation
• MRI-based radiomics model to preoperatively predict mesenchymal transition subtype in high-grade serous ovarian cancer.

  2024cites this paper
• The multiple facets of ovarian high grade serous carcinoma: a review on morphological, immunohistochemical and molecular features.

  2024cites this paper
• Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and Challenges

  2024cites this paper
• Artificial intelligence-based histopathological subtyping of high-grade serous ovarian cancer.

  2024cites this paper
• A deep learning-based assessment pipeline for intraepithelial and stromal tumor-infiltrating lymphocytes in high-grade serous ovarian carcinoma.

  2024cites this paper
• Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis

  2023cites this paper
• Transcriptome profiling and characterization of peritoneal metastasis ovarian cancer xenografts in humanized mice

  2023cites this paper
• Mesenchymal ovarian cancer cells promote CD8+ T cell exhaustion through the LGALS3-LAG3 axis

  2023cites this paper
• Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers

  2023influential citation
• Unpacking the Complexity of Epithelial Plasticity: From Master Regulator Transcription Factors to Non-Coding RNAs

  2023cites this paper
• The Clinical Use of Genomic Profiling for Prognosis Prediction in High Grade Serous Ovarian Cancer

  2023cites this paper
• Poor-prognosis molecular subtypes in adenocarcinomas of pancreato-biliary and gynecological origin: A systematic review.

  2023cites this paper
• Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging

  2023influential citation
• Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study

  2023cites this paper
• Subtyping of high grade serous ovarian carcinoma: histopathological and immunohistochemical approach

  2022influential citation
• Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints

  2022influential citation
• Computational tumor stroma reaction evaluation led to novel prognosis-associated fibrosis and molecular signature discoveries in high-grade serous ovarian carcinoma

  2022cites this paper
• Diffusion‐Weighted Magnetic Resonance Imaging and Morphological Characteristics Evaluation for Outcome Prediction of Primary Debulking Surgery for Advanced High‐Grade Serous Ovarian Carcinoma

  2022cites this paper
• Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics

  2022cites this paper
• Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.

  2022cites this paper
• Magnetic Resonance Imaging and Diffusion Weighted Imaging-Based Histogram in Predicting Mesenchymal Transition High-Grade Serous Ovarian Cancer.

  2022cites this paper
• Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype

  2022cites this paper
• Better or worse? The prognostic role of the mesenchymal subtype in patients with high‐grade serous ovarian carcinoma: A systematic review and meta‐analysis

  2022cites this paper
• The Evolution of Ovarian Carcinoma Subclassification

  2022cites this paper
• Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1

  2022cites this paper
• Prognostic significance of intra-tumoral budding in high-grade serous ovarian carcinomas

  2022cites this paper
• Fatty Acid Metabolism in Ovarian Cancer: Therapeutic Implications

  2022cites this paper
• Tissue miR-200c-3p and circulating miR-1290 as potential prognostic biomarkers for colorectal cancer

  2022cites this paper
• Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer

  2021cites this paper
• Over-expression of CXCL2 is associated with poor prognosis in patients with ovarian cancer

  2021cites this paper
• Survival and biomarker analysis for ovarian mucinous carcinoma according to invasive patterns: retrospective analysis and review literature

  2021cites this paper
• Oncogenic B-Myb Is Associated With Deregulation of the DREAM-Mediated Cell Cycle Gene Expression Program in High Grade Serous Ovarian Carcinoma Clinical Tumor Samples

  2021cites this paper
• Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition

  2021cites this paper
• Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations

  2021cites this paper
• Tailor-Made Therapy According to Genetic Alteration in Epithelial Ovarian Cancers

  2021cites this paper
• Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer

  2021cites this paper
• Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms

  2021cites this paper
• Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC)

  2021cites this paper
• CELL-STIFFNESS AND MORPHOLOGICAL ARCHITECTURAL PATTERNS IN CLINICAL SAMPLES OF HIGH GRADE SEROUS OVARIAN CANCERS.

  2021cites this paper
• B7-H3 Suppresses Antitumor Immunity via the CCL2–CCR2–M2 Macrophage Axis and Contributes to Ovarian Cancer Progression

  2021cites this paper
• Integration of Genomic Profiling and Organoid Development in Precision Oncology

  2021cites this paper
• Upregulation of cyclase-associated actin cytoskeleton regulatory protein 2 in epithelial ovarian cancer correlates with aggressive histologic types and worse outcomes.

  2020cites this paper
• Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease.

  2020cites this paper
• Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer

  2020cites this paper
• Clinicopathological and Immunohistochemical Study of High Grade Serous Ovarian Carcinoma

  2020influential citation
• Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer

  2020cites this paper
• Potential Novel Ovarian Cancer Treatment Targeting Myeloid-Derived Suppressor Cells

  2020cites this paper
• Modelling Epithelial Ovarian Cancer in Mice: Classical and Emerging Approaches

  2020cites this paper
• Outline of Surgical Treatments

  2019cites this paper
• The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1).

  2019cites this paper
• The Vicious Cross-Talk between Tumor Cells with an EMT Phenotype and Cells of the Immune System

  2019cites this paper
• Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes

  2019cites this paper
• Endovascular trophoblast expresses CD59 to evade complement-dependent cytotoxicity.

  2019cites this paper
• Surgery for Gynecologic Cancer

  2019cites this paper
• Cathepsin B defines leader cells during the collective invasion of salivary adenoid cystic carcinoma

  2019cites this paper
• An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers

  2019cites this paper
• High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints

  2019cites this paper
• ADP-Ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers

  2019cites this paper
• A Comprehensive Review of Ovarian Serous Carcinoma

  2019cites this paper
• New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach

  2019cites this paper
• Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells

  2018cites this paper
• Title Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells

  2018cites this paper
• Mechanisms of B-Myb oncogenicity in ovarian cancer

  2018cites this paper
• Current Concept of Precancerous and Early Stage of Serous Ovarian Carcinoma

  2018cites this paper
• Molecular Pathogenesis of Ovarian Cancer: An Inextricable Maze

  2018cites this paper
• Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?

  2018cites this paper
• Pathology of Female Cancers

  2018influential citation
• Morphology and tumour‐infiltrating lymphocytes in high‐stage, high‐grade serous ovarian carcinoma correlated with long‐term survival

  2018cites this paper
• Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation

  2018cites this paper
• Subtypes of Ovarian Cancer and Ovarian Cancer Screening

  2017cites this paper
• Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.

  2017cites this paper
• Diversity in Pathology and Genomics in Ovarian Cancer

  2017cites this paper
• Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum

  2017cites this paper
• Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes

  2017cites this paper
• Similarity and diversity of the tumor microenvironment in multiple metastases: critical implications for overall and progression-free survival of high-grade serous ovarian cancer

  2016cites this paper
• Galectin-3, Cardiac Function, and Fibrosis.

  2016cites this paper
• Identificación de biomarcadores relacionados con la transición epitelio-mesénquima y caracterización de modelos celulares tridimensionales in vitro en cáncer de ovario avanzado

  2016cites this paper
• Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells

  2016cites this paper